in accordan	ice with Regulation (EC) I	No. 1907/2006 and Regulation (EU) No	. 2020/878		(Language:El
K	isaval	DUEPOL ACQUA SUELOS SATINAD Code : 1656	0		
Version:	3 Revi	sion: 11/03/2024	Previous revision: 23/1	2/2022	Date of printing: 11/03/202
mixtures.T	his product does not me	on (EC) No. 1907/2006 (REACH), a s et the classification criteria of Regula rements regarding the content of eac	afety data sheet (SDS) must be provid tion (EC) No. 1272/2008 (CLP).Theref h section are not applicable.	ed for dange ore, this docι	rous substances or iment is outside the scope o
SECTION	1: IDENTIFICATION OF	THE SUBSTANCE/MIXTURE AND	OF THE COMPANY/UNDERTAKING		
	PRODUCT IDENTIFIE DUEPOL ACQUA SUEI Code : 1656				
		ED USES OF THE SUBSTANCE	OR MIXTURE AND USES ADVISE		۲.
	Intended uses (main t Liquid paint. <u>Sectors of use:</u> Consumer uses (SU21) Professional uses (SU2 <u>Uses advised against</u>	echnical functions): [] Indus , 2),	rial [X] Professional [X] Consumer	<u>rs</u>	_
	consistent with the safe	ty guidelines provided.	e, according to Annex XVII of Regula		
	Not restricted.				
	PINTURAS ISAVAL, S.I c/Velluters, Parcela 2-14 Phone number: +34 96	4- P.I. Casanova - 46394 Ribarroja d 1640001 - Fax: +34 96 1640002 - wv <u>e person responsible for the Safet</u>	el Turia (Valencia) ESPAÑA /w.isaval.es		
	EMERGENCY TELEF				
	+34 96 1640001 8:00-1				
SECTION	2 : HAZARDS IDENTIF	CATION			
2.1	CLASSIFICATION OF	THE SUBSTANCE OR MIXTUR	<u>=:</u>		
	under ordinary conditior		ording to the Regulation (EC) no. 2020 mical, health safety or environmental h		
	This product does not re <u>- Hazard statements:</u> None. <u>- Precautionary statementary</u> P102 P271 P280 P273 <u>- Supplementary state</u>	nents: Keep out of reach of children. Use only outdoors or in a well-ventila Wear protective gloves and eye prot Avoid release to the environment.		lo. 1272/2008	3~2022/692 (CLP).
			ne, Reaction mass of 5-chloro-2-methy C 220-239-6] (3:1), 1,2-benzisothiazol-		
	OTHER HAZARDS:		паше.		
	Hazards which do not re - Other physicochemic No other relevant adver - Other adverse huma No other relevant adver - Other negative envir Does not contain substa Endocrine disrupting p	cal hazards: se effects are known. in health effects: se effects are known. onmental effects: ances that fulfil the PBT/vPvB criteria properties:	ontribute to the overall hazards of the r		
1					

$\square$	<b>ISAVA</b>	Code : 1656							
ersion			Previous revision: 23/12/2022	Date	of printing: 11/03/20				
CTION		ORMATION ON INGREDIENTS							
.1	SUBSTANCES:								
	Not applicable (mixture	).							
.2	MIXTURES:								
	This product is a mixtur Chemical description								
		d acrylic resin in aqueous media.							
	HAZARDOUS INGRE								
		in a percentage higher than the exemption limit:							
ľ		1,2-benzisothiazol-3(2H)-one		CLP00	Skin Sens. 1, H31				
		CAS: 2634-33-5, EC: 220-120-9			C ≥0,05				
		CLP: Danger: Acute Tox. (oral) 4:H302 (ATE=567 mg/kg) Eye Dam. 1:H318   Skin Sens. 1:H317   Aquatic Acute 1:H							
-			1400	DEAQU	Skin Sono 1 H21				
		1,2-benzisothiazol-3(2H)-one CAS: 2634-33-5, EC: 220-120-9, REACH: 01-212076154	0-60	REACH	Skin Sens. 1, H31 C ≥0,05 °				
		CLP: Danger: Acute Tox. (oral) 4:H302 (ATE=490 mg/kg)							
	I	Eye Dam. 1:H318   Skin Sens. 1:H317   Aquatic Acute 1:F	H400 (M=10)						
Ī	C < 0,0015 %	Reaction mass of 5-chloro-2-methyl-2H-isothiazolin-3-one	e [EC 247-500-7]	ATP13	Skin Corr. 1C, H31				
		and 2-methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)			C ≥0,6 Skin Irrit. 2, H31				
		CAS: 55965-84-9, EC: 611-341-5 CLP: Danger: Acute Tox. (inh.) 2:H330 (ATE=50 mg/m3)	Aguta Tax (akin)		0,06 % ≤ C < 0,6				
		2:H310 (ATE=140 mg/kg)   Acute Tox. (oral) 3:H301 (ATE			Eye Dam. 1, H31 C ≥0,6				
		Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute 1:H400	) (M=100) Aquatic		Eye Irrit. 2, H31 0,06 % ≤ C < 0,6				
		Chronic 1:H410 (M=100)   EUH071   Skin Sens. 1A:H317	(Note B)		Skin Sens. 1A, H31				
-					C ≥0,0015				
	Impurities:								
		components or impurities which will influence the classific	cation of the product.						
	Stabilizers:								
	None. Reference to other sections:								
		ee sections 8, 11, 12 and 16.							
		ERY HIGH CONCERN (SVHC):							
	List updated by ECHA	· /							
		ibject to authorisation, included in Annex XIV of Reg	ulation (EC) no. 1907/20	<u>06:</u>					
	None.	-							
	Substances SVHC ca	andidate to be included in Annex XIV of Regulation (	<u>EC) no. 1907/2006:</u>						
	None.								
		CCUMULABLE AND TOXIC PBT, OR VERY PERSIS	STENT AND VERY BIOA	CCUMULAB	<u>LE VPVB</u>				
	SUBSTANCES:	ences that fulfil the DDT/ (D) D suiteria							
		ances that fulfil the PBT/vPvB criteria. uded in the (EU) REGULATION 2019/1021~2020/78	4 on persistent organic n	ollutante					
	None.		Heron persistent organic p	oliutants.					
	1 4: FIRST AID MEASUF	2FS							
.1		IRST AID MEASURES:							
		occur after exposure, so that in case of direct exposure t	to the product, when in dou	ht or when s	mntoms persist				
. '				bt, or when sy	inploms persist,				
. 1		tention.Never give anything by mouth to an unconscious	•						
				leasures					
. 1	Route of exposure	Symptoms and effects, acute and delayed	Description of first-aid m	10000100					
	Route of exposure	Symptoms and effects, acute and delayed	-		fer the person				
			Description of first-aid m Should there be any syn affected to the open air.		fer the person				
	Route of exposure	Symptoms and effects, acute and delayed It is not expected that symptoms will occur under	Should there be any syn affected to the open air. Remove contaminated c	nptoms, trans clothing.Wash	thoroughly the				
	Route of exposure	Symptoms and effects, acute and delayed It is not expected that symptoms will occur under normal conditions of use.	Should there be any syn affected to the open air. Remove contaminated o affected area with plenty	nptoms, trans clothing.Wash / of cold or luk	thoroughly the kewarm water and				
	Route of exposure Inhalation: Skin:	Symptoms and effects, acute and delayed It is not expected that symptoms will occur under normal conditions of use. It is not expected that symptoms will occur under normal conditions of use.	Should there be any syn affected to the open air. Remove contaminated o affected area with plenty neutral soap, or use a su	nptoms, trans clothing.Wash / of cold or luk uitable skin clo	thoroughly the kewarm water and eanser.				
	Route of exposure	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.	Should there be any syn affected to the open air. Remove contaminated o affected area with plenty neutral soap, or use a su Remove contact lenses.	nptoms, trans clothing.Wash / of cold or luk uitable skin cl Rinse eyes co	thoroughly the kewarm water and eanser. opiously by				
	Route of exposure Inhalation: Skin:	Symptoms and effects, acute and delayed It is not expected that symptoms will occur under normal conditions of use. It is not expected that symptoms will occur under normal conditions of use.	Should there be any syn affected to the open air. Remove contaminated o affected area with plenty neutral soap, or use a su Remove contact lenses. irrigation with plenty of o	nptoms, trans clothing.Wash / of cold or luk uitable skin clu Rinse eyes co clean, fresh wa	thoroughly the kewarm water and eanser. opiously by ater, holding the				
	Route of exposure Inhalation: Skin:	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.	Should there be any syn affected to the open air. Remove contaminated o affected area with plenty neutral soap, or use a su Remove contact lenses.	nptoms, trans clothing.Wash / of cold or luk uitable skin clu Rinse eyes ca clean, fresh wa persists, cons	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
	Route of exposure Inhalation: Skin: Eyes: Ingestion:	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a su Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting aspiration.Keep the pati	nptoms, trans clothing.Wash / of cold or luk uitable skin clo Rinse eyes co clean, fresh wa persists, cons , due to the ris	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
.2	Route of exposure Inhalation: Skin: Eyes: Ingestion:	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a su Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting aspiration.Keep the pati	nptoms, trans clothing.Wash / of cold or luk uitable skin clo Rinse eyes co clean, fresh wa persists, cons , due to the ris	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
	Route of exposure Inhalation: Skin: Eyes: Ingestion: <u>MOST IMPORTANT</u> The main symptoms an	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D ad effects are indicated in sections 4.1 and 11.1	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a syn Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting, aspiration.Keep the pation DELAYED:	nptoms, trans clothing.Wash / of cold or luk uitable skin cli Rinse eyes ca clean, fresh wa persists, cons due to the ris ent at rest.	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
	Route of exposure Inhalation: Skin: Eyes: Ingestion: <u>MOST IMPORTANT</u> The main symptoms an	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a syn Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting, aspiration.Keep the pation DELAYED:	nptoms, trans clothing.Wash / of cold or luk uitable skin cli Rinse eyes ca clean, fresh wa persists, cons due to the ris ent at rest.	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
.2	Route of exposure Inhalation: Skin: Eyes: Ingestion: <u>MOST IMPORTANT</u> The main symptoms an	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D ad effects are indicated in sections 4.1 and 11.1	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a syn Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting, aspiration.Keep the pation DELAYED:	nptoms, trans clothing.Wash / of cold or luk uitable skin cli Rinse eyes ca clean, fresh wa persists, cons , due to the ris ent at rest.	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
.2	Route of exposure Inhalation: Skin: Eyes: Ingestion: <u>MOST IMPORTANT</u> The main symptoms an <u>INDICATION OF ANY</u> <u>Notes to physician:</u> Treatment should be di	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D of effects are indicated in sections 4.1 and 11.1         TIMMEDIATE MEDICAL ATTENTION AND SPECIA         rected at the control of symptoms and the clinical condition	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a sy Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting aspiration.Keep the pation DELAYED: ALTREATMENT NEEDE	nptoms, trans clothing.Wash / of cold or luk uitable skin cli Rinse eyes ca clean, fresh wa persists, cons , due to the ris ent at rest.	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				
.2	Route of exposure Inhalation: Skin: Eyes: Ingestion: MOST IMPORTANT The main symptoms an INDICATION OF AN Notes to physician:	Symptoms and effects, acute and delayed         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         It is not expected that symptoms will occur under normal conditions of use.         If swallowed in high doses, may cause gastrointestinal disturbances.         SYMPTOMS AND EFFECTS, BOTH ACUTE AND D of effects are indicated in sections 4.1 and 11.1         (IMMEDIATE MEDICAL ATTENTION AND SPECIA)         rected at the control of symptoms and the clinical condition ndications:	Should there be any syn affected to the open air. Remove contaminated of affected area with plenty neutral soap, or use a sy Remove contact lenses. irrigation with plenty of of eyelids apart.If irritation Do not induce vomiting aspiration.Keep the pation DELAYED: ALTREATMENT NEEDE	nptoms, trans clothing.Wash / of cold or luk uitable skin cli Rinse eyes ca clean, fresh wa persists, cons , due to the ris ent at rest.	thoroughly the kewarm water and eanser. opiously by ater, holding the sult a physician.				

Т.		Code : 1656		
ersior	n: 3 Re	evision: 11/03/2024	Previous revision: 23/12/2022	Date of printing: 11/03/202
ECTION	N 5: FIREFIGHTING MI	EASURES		
5.1	EXTINGUISHING N	<u>IEDIA:</u>		
		surroundings, all extinguishing agents		
5.2		S ARISING FROM THE SUBSTA		anida. Oadaan dianida
			, hazardous products may be produced: carbon mon ydrochloric acid.Exposure to combustion or decomp	
i.3	ADVICE FOR FIRE	FIGHTERS:		
	Special protective e	equipment:		
	protective glasses or sheltered position or t	face masks and boots.If the fire-proo from a safe distance.The standard EN	hing may be required, appropriate independent brea of protective equipment is not available or is not bein N469 provides a basic level of protection for chemica	g used, combat fire from a
			sources of heat or fire.Bear in mind the direction of the	ne wind.Do not allow fire-
CTION	N 6: ACCIDENTAL REL	EASE MEASURES		
.1	PERSONAL PREC	AUTIONS, PROTECTIVE EQUIP	MENT AND EMERGENCY PROCEDURES:	
			ours.Keep people without protection in opposition to	the wind direction.
.2	ENVIRONMENTAL			
	lakes, rivers or sewag	ges, inform the appropriate authorities	ater and soil.In the case of large scale spills or when s in accordance with local regulations.	the product contaminates
5.3	-	ATERIAL FOR CONTAINMENT A		to ) Koon the remains in a
	closed container.	spills with absorbent materials (sawd	ust, earth, sand, vermiculite, diatomaceous earth, et	ic). Keep the remains in a
6.4	REFERENCE TO C	THER SECTIONS:	<u> </u>	
		on in case of emergency, see section	1.	
		fe handling, see section 7.		
		s and personal protection measures,		
		blow the recommendations in section	113.	
CTION	N 7: HANDLING AND S			
.1		OR SAFE HANDLING:		
		ing legislation on health and safety a	t work.	
	- General recomme			
		kage or escape.Keep the container tig		
		<u>s for the prevention of fire and exp</u>		<b>.</b>
			nd does not sustain the combustion reaction by oxyge of Directive 2014/34/EU concerning equipment and	
		explosive atmospheres.	3 of Directive 2014/34/EO concerning equipment and	a protective systems intende
		s for the prevention of toxicologica	ıl risks:	
			wash hands with soap and water. For exposure cont	rols and personal protection
	measures, see sectio	<b>e</b>		· · · · · · · · · · · · · · · · · · ·
		s for the prevention of environmen		
		•	se of accidental spillage, follow the instructions indic	cated in section 6.
.2		SAFE STORAGE, INCLUDING A		
		to avoid leakages, the containers, af	ch of children. Keep away from sources of heat. If po fter use, should be closed carefully and placed in a v	
	- Class of store:			
	According to current I	-		
	- Maximum storage	period:		
	# 24 Months.			
	- Temperature inter			
	min:5 °C, max:40 °C			
	- Incompatible mate	izing agents, acids, alkalis.		
	- Type of packaging			
	According to current I			
	-	/eso III): Directive 2012/18/EU:		
		ict for non industrial use).		
	SPECIFIC END US			
3				
.3	For the use of this pro		art from that already indicated are not available.	

	/al	DUEPOL ACQUA SUELO	S SATINADO					
pi	nturas	Code : 1656					Datasta	
		sion: 11/03/2024 DLS/PERSONAL PROTE	CTION	Pi	revious revision:	23/12/2022	Date of p	orinting: 11/03/20
CONTROL F			CHON					
effectiveness made to EN68 exposure to c determination	of the venti 89, EN1404 chemical an of dangero	edients with exposure lin lation or other control me 2 and EN482 standard c d biological agents. Refe ous substances. POSURE LIMIT VALU	easures and/or the i oncerning methods rence should be als	necessity to for assesing	use respiratory g the exposure	/ protective equipsion by inhalation to	ipment. Refe	rence should gents, and
EH40/2005 W Kingdom) 201		d Y	′ear   WEL-TWA		WEL-STEL		Remarks	
1,2-benzisoth		000	ppm	mg/m3 0,1		mg/m3		Recommend
1,2-benzisoth	. ,			0,1		-		Recommend
Reaction mas -isothiazolin-3	ss of 5-chloi 3-one [EC 2	ro-2-methyl-2H 47-500-7] and -one [EC 220-		0,08		0,23	5	Recommend
Derived no-ef	ed <u>NO-EFFE(</u> ffect level ([	<u>CT LEVEL (DNEL):</u> DNEL) is a level of exposi L values may differ from						
recommended health, the OE	d by a parti EL values a	cular company, a governi re derived by a process o	ment regulatory age	ency or an or	ganization of e	experts. Althoug	h considered	
- DERIVED NO Systemic effect		EVEL, WORKERS:-	DNEL Inhalation mg/m3		DNEL Cutaneo mg/kg bw/d	ous	DNEL Oral mg/kg bw/d	
Systemic ellect	is, acute and	CHIONIC.						
1.2-benzisothia	azol_3(2H)_or	0	s/r (a)	6 81 (c)	s/r (a)	0.966 (c)	- (a)	- (c)
one [EC 247-50	of 5-chloro-2 00-7] and 2-r	e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one	s/r (a) - (a)	6,81 (c) - (c)	s/r (a) - (a)	0,966 (c) - (c)	- (a) - (a)	- (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6]	of 5-chloro-2 00-7] and 2-r ] (3:1)	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one		, .,	. ,	,		- (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia	of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or D-EFFECT LE	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one	- (a)	- (c)	- (a)	- (c) - (c)	- (a)	
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia	of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or D-EFFECT LE and chronic: azol-3(2H)-or	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, WORKERS:- Local e	- (a) - (a) DNEL Inhalation	- (c)	- (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a)	- (c) - (c) <u>- us</u> a/r (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a)	- (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50	6 of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or D-EFFECT LE and chronic: azol-3(2H)-or 6 of 5-chloro-2 00-7] and 2-r	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, WORKERS:- Local	- (a) - (a) <u>DNEL Inhalation</u> mg/m3	- (c) - (c)	- (a) <u> DNEL Cutaneo</u> mg/cm2	- (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2	- (C)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass	6 of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or D-EFFECT LE and chronic: azol-3(2H)-or 6 of 5-chloro-2 00-7] and 2-r ] (3:1)	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 s/r (a)	- (c) - (c) s/r (c)	- (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a)	- (c) - (c) <u>- us</u> a/r (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a)	- (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO POPULATION:	6 of 5-chloro-2 200-7] and 2-r ] (3:1) azol-3(2H)-or D-EFFECT LE and chronic: azol-3(2H)-or 6 of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or D-EFFECT LE - Systemic e	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, GENERAL ffects, acute and chronic:	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3	- (c) - (c) s/r (c) - (c) - (c)	- (a) - (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a) - (a) <u>DNEL Cutaneo</u> mg/kg bw/d	- (c) - (c) <u>uus</u> a/r (c) - (c) - (c) <u>uus</u>	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d	- (c) - (c) - (c) - (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO POPULATION: 1,2-benzisothia Reaction mass one [EC 247-50	6 of 5-chloro-2 200-7] and 2-r ] (3:1) -EFFECT LE azol-3(2H)-or -EFFECT LE azol-3(2H)-or 5 of 5-chloro-2 200-7] and 2-r ] (3:1) azol-3(2H)-or -EFFECT LE -Systemic e azol-3(2H)-or 5 of 5-chloro-2 00-7] and 2-r	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, GENERAL ffects, acute and chronic:	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 s/r (a) - (a) <u>DNEL Inhalation</u>	- (c) - (c) s/r (c) - (c) - (c)	- (a) - (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a) - (a) <u>DNEL Cutaneo</u>	- (c) - (c) <u>- (c)</u> - (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u>	- (c) - (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO POPULATION: 1,2-benzisothia Reaction mass	6 of 5-chloro-2 200-7] and 2-r ] (3:1) -EFFECT LE and chronic: azol-3(2H)-or -EFFECT LE azol-3(2H)-or 5 of 5-chloro-2 00-7] and 2-r ] (3:1) -EFFECT LE - Systemic e azol-3(2H)-or 5 of 5-chloro-2 00-7] and 2-r ] (3:1)	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, GENERAL ffects, acute and chronic: e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 - (a) - (a) <u>DNEL Inhalation</u> mg/m3 s/r (a)	- (c) - (c) s/r (c) - (c) - (c) 1,2 (c)	- (a) - (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a) - (a) <u>DNEL Cutaneo</u> mg/kg bw/d s/r (a)	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d 2 (a)	- (c) - (c) - (c) - (c) - (c) s/r (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO POPULATION: 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - LOCAL EFFE effects, acute a	of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or )-EFFECT LE and chronic: azol-3(2H)-or 6 of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or 6 of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or 6 of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or CTS, ACUTE and chronic:	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, GENERAL ffects, acute and chronic: e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e E AND CHRONIC:- Local	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3	- (c) - (c) s/r (c) - (c) - (c) 1,2 (c) - (c) - (c) - (c)	- (a) - (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a) - (a) <u>DNEL Cutaneo</u> mg/kg bw/d s/r (a) - (a) <u>DNEL Cutaneo</u> mg/cm2	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d 2 (a) - (a) <u>DNEL Eyes</u> mg/cm2 <u>DNEL Eyes</u> mg/cm2	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO POPULATION: 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - LOCAL EFFE effects, acute a 1,2-benzisothia	of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or )-EFFECT LE and chronic: azol-3(2H)-or of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or of 5-chloro-2 00-7] and 2-r [ (3:1) azol-3(2H)-or of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or cTTS, ACUTE and chronic: azol-3(2H)-or	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, GENERAL ffects, acute and chronic: e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e E AND CHRONIC:- Local e	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a)	- (c) - (c) s/r (c) - (c) 1,2 (c) - (c) - (c) s/r (c)	- (a) - (a) DNEL Cutaneo mg/cm2 a/r (a) - (a) DNEL Cutaneo mg/kg bw/d s/r (a) - (a) DNEL Cutaneo mg/cm2 a/r (a) - (a)	- (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d 2 (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a)	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia Reaction mass one [EC 247-50 [EC 247-50]	acol-3(2H)-or azol-3(2H)-or -EFFECT LE azol-3(2H)-or -EFFECT LE azol-3(2H)-or of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or color 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or color 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or color 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or color 5-chloro-2 00-7] and 2-r azol-3(2H)-or color 5-chloro-2 00-7] and 2-r	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e EVEL, GENERAL ffects, acute and chronic: e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e E AND CHRONIC:- Local	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3	- (c) - (c) s/r (c) - (c) - (c) 1,2 (c) - (c) - (c) - (c)	- (a) - (a) <u>DNEL Cutaneo</u> mg/cm2 a/r (a) - (a) <u>DNEL Cutaneo</u> mg/kg bw/d s/r (a) - (a) <u>DNEL Cutaneo</u> mg/cm2	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d 2 (a) - (a) <u>DNEL Eyes</u> mg/cm2 <u>DNEL Eyes</u> mg/cm2	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - LOCAL EFFE effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6]	6 of 5-chloro-2 200-7] and 2-r ] (3:1) azol-3(2H)-or -EFFECT LE azol-3(2H)-or 5 of 5-chloro-2 200-7] and 2-r ] (3:1) azol-3(2H)-or 5 of 5-chloro-2 200-7] and 2-r ] (3:1)	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e E AND CHRONIC:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a) - (a) <u>DNEL Inhalation</u> mg/m3 S/r (a)	- (c) - (c) s/r (c) - (c) 1,2 (c) - (c) - (c) s/r (c)	- (a) - (a) DNEL Cutaneo mg/cm2 a/r (a) - (a) DNEL Cutaneo mg/kg bw/d s/r (a) - (a) DNEL Cutaneo mg/cm2 a/r (a) - (a)	- (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d 2 (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a)	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)
Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia - DERIVED NO effects, acute a 1,2-benzisothia Reaction mass one [EC 247-50 [EC 220-239-6] 1,2-benzisothia Reaction mass one [EC 247-50 [EC 20-239-6] 1,2-benzisothia Reaction mass one [EC 247-50 [EC 20-239-6] 1,2-benzisothia Reaction mass one [EC 247-50 [EC 20-239-6] 1,2-benzisothia	of 5-chloro-2 00-7] and 2-r ] (3:1) -EFFECT LE and chronic: azol-3(2H)-or of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or cTS, ACUTE and chronic: azol-3(2H)-or cTS, ACUTE and chronic: azol-3(2H)-or of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or s of 4-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or s of 5-chloro-2 00-7] and 2-r ] (3:1) azol-3(2H)-or s of 4-chloro-2 00-7] and 2-r ] (3:1)	2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one EVEL, WORKERS:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one e E AND CHRONIC:- Local e 2-methyl-2H-isothiazolin-3- nethyl-2H-isothiazolin-3- nethyl-2H-isothiazol-3-one	- (a) - (a) <u>DNEL Inhalation</u> mg/m3 s/r (a) - (a) <u>DNEL Inhalation</u> mg/m3	- (c) - (c) s/r (c) - (c) 1,2 (c) - (c) 1,2 (c) - (c) - (c) s/r (c) - (c) - (c) - (c)	- (a) - (a) <u>DNEL Cutaneo</u> mg/cm <sup>2</sup> a/r (a) - (a) <u>DNEL Cutaneo</u> mg/kg bw/d S/r (a) - (a) <u>DNEL Cutaneo</u> mg/cm <sup>2</sup> a/r (a) - (a) <u>DNEL Cutaneo</u> mg/cm <sup>2</sup> a/r (a) - (a)	- (c) - (c)	- (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a) <u>DNEL Eyes</u> mg/kg bw/d 2 (a) - (a) <u>DNEL Eyes</u> mg/cm2 m/r (a) - (a)	- (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c) - (c)

<mark>  i</mark> s	aval	DUEPOL ACQUA SUELOS Code : 1656	SATINADO					
ersion: 3	Revi	sion: 11/03/2024		Pr	revious revision: 23/	12/2022	Date of p	rinting: 11/03/20
isothia	zolin-3-one [EC	nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6]		-		-		-
	nzisothiazol-3(2	,		-		-		-
<u>- WAST</u> AND SE WATER	EDIMENTS IN F	<u>TMENT PLANTS (STP)</u> RESH- AND MARINE	PNEC STP mg/l		PNEC Sediments mg/kg dw/d		PNEC Sedim mg/kg dw/d	<u>ents</u>
1,2-ber Reaction isothiaz methyl- (3:1)	nzisothiazol-3(2 on mass of 5-cl zolin-3-one [EC -2H-isothiazol-3	hloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6]		1.03 -		0.0499 -		0.00499 -
	nzisothiazol-3(2	-		-		-		-
TERRE		<u>ECT CONCENTRATION.</u> <u>IISMS:- Air, soil and</u> d humans <u>:</u>	PNEC Air mg/m3		<u>PNEC Soil</u> mg/kg dw/d		PNEC Oral mg/kg dw/d	
Reaction isothia	zolin-3-one [EC	2H)-one hloro-2-methyl-2H- 2 247-500-7] and 2- 3-one [EC 220-239-6]		s/r -		3 -		n/b -
	nzisothiazol-3(2	PH)-one		-		-		-
n/b - Pl s/r - PN	NEC not derive	ble (without data of registra ed (not bioaccumulative po d (not identified hazard).	ation REACH). tential).				1	
	EERING MEA							
Avoid th <u>- Prote</u> It is recu- <u>- Prote</u> It is recu- exposed	ction of hands commended to in d areas of the sk	<u>tory system:</u> /apours. <u>nd face:</u> stall water taps or sources w <u>and skin:</u> stall water taps or sources w in.Barrier creams should no	ith clean water clos t be applied once e	e to the w e to the w xposure ha	rorking area. rorking area.Barrie as occurred.			
As a ge with the charact	neral measure of corresponding	POSURE CONTROLS: R on prevention and safety in the marking. For more information PE, protection class, marking PE.	ne work place, we re on on personal prot	ecommeno ective equ	d the use of a bas uipment (storage,	use, cleani	ing, maintenan	ice, type and
Mask:		# A-type filter mask (b ✓ than 65°C (EN14387) ppm, Class 3: high ca class must be selected in accordance with th	Class 1: low capa pacity up to 1000 d depending on the specifications su	acity up to 0 ppm.In ne type ar upplied by	o 1000 ppm, Cla order to obtain a nd concentratior y the filter produ	iss 2: med a suitable n of the con cers.	lium capacity protection lev ntaminating a	up to 5000 rel, the filter agents presen
Safety	goggles:	Safety goggles design (EN166).Clean daily a manufacturer.						
Face s	hield:	No.						
Gloves	:	# Gloves resistant ag ✓ expected, gloves of p min.When short conta	rotection level 5 o	r higher s ct is expe	should be used, cted, use gloves	with a brea s with a pro	akthrough tim otection level	ne of >240

n (ÈC) No. 1907/2006 and Regulation (EU)	No. 2020/878 (Language:EN
DUEPOL ACQUA SUELOS SATIN Code : 1656	IADO
Revision: 11/03/2024	Previous revision: 23/12/2022 Date of printing: 11/03/2024
No.	
No.	
No.	
he product is handled at room temperatu ITAL EXPOSURE CONTROLS: ge in the environment. Avoid any release soil: nation of soil. escape into drains, sewers or water course agement Act: as not contain any substance included in the 13/39/EU. the atmosphere: tility, emissions to the atmosphere while the ready for use*): he Directive 2004/42/EC, on the limitation ES (defined in the Directive 2004/42/EC, A ady for use*): (DUEPOL ACQUA SUELO 0 / 7 in volume): 6,6 g/l* (VOC max.140 g/ Linstallations): used in an industrial installation, it must be assions of volatile compounds due to the u	nto the atmosphere. es. he list of priority substances in the field of water policy under Directive andling and use may result. Avoid any release into the atmosphere. of emissions of volatile compounds due to the use of organic solvents: PAINTS unnex I.1): Emission subcategory j) Two-pack performance coating, water-borne. S SATINADO Cod. 1656 / ENDURECEDOR DUEPOL ACQUA MATE SEDOSO
	DUEPOL ACQUA SUELOS SATIN         Code : 1656         Revision: 11/03/2024         No.         No.         No.         No.         No.         No.         No.         No.         Italian         No.         No.         No.         Italian         No.         No.         Italian         No.         No.         Italian         No.         Italian         No.         No.         No.         No.         No.         Italian         No.         Italian         Revision: tanaded at room temperature         Italian         No.         Italian         No.         Italian         No.         Italian         Italian         Italian         Italian         No.         Italian         Italian         Italian         Itanos of soil.         Italian     <

	pinturas	DUEPOL ACQUA SUELOS SATINAL Code : 1656	00	
rsion: 3	Rev	vision: 11/03/2024	Previous revision: 23/12/2022	Date of printing: 11/03/20
TION 9: PHY	SICAL AND CH	IEMICAL PROPERTIES		
INFO	RMATION ON	BASIC PHYSICAL AND CHEMICA	L PROPERTIES:	
	arance			
	al state:		Liquid	
Colour			See the colour in the package	
Odour	:		Characteristic	
Odour	threshold:		Not available (mixture).	
Chano	ge of state			
Freezi	ng point:		Not available (mixture).	
Initial b	oiling point:		> 100* °C at 760 mmHg	
	<u>nmability:</u>			
Flashp			Not flammable	
		lity or explosive limits:	Not available	
-	nition temperatu	ire:	Not applicable (do not sustain combustion).	
<u>Stabili</u>				
	position temper	ature:	1,600,00* °C	
<u>pH-va</u>	lue			
pH:			10 at 20°C	
- Visc				
	nic viscosity:		Not available.	
	atic viscosity:		Not available.	
	<u>ıbility(ies):</u>			
	ity in water		Miscible	
	lubility:		Not applicable (inorganic product).	
	on coefficient: n-	octanol/water:	Not applicable (mixture).	
- Vola				
	r pressure:		17,535* mmHg at 20°C	
	r pressure:		12,113* kPa at 50°C	
	ration rate:		Not available (lack of data).	
Densi			4 404* -+ 00/400	Deletine meter
	e density:		1,194* at 20/4°C	Relative water
	e vapour densit le characteristi		Not available.	
Particle			Not applicable.	
			Not applicable.	
	<u>losive propertie</u> ailable.	<u>25.</u>		
	dizing propertie			
	assified as oxidiz			
INOL CIE				
*Estim	ated values bas	ed on the substances composing the	mixture.	
	R INFORMAT			
		g physical hazard classes		
	ditional informati			
	security featur			
	supply):	<u></u>	0.5 % Weight	
	supply):		6,0 g/l	
Nonvo			41,72 * % Weight	1h. 60⁰C
	lues indicated d	lo not always coincide with product sp	ecifications. The data for the product specifications c	an be found in the
The va			on concerning physical and chemical properties relate	ed to safety and
corres				

К		DUEPOL ACQUA SUELO Code : 1656	DS SATINADO		
ersior	n: 3 Rev	ision: 11/03/2024	Pre	evious revision: 23/12/2022	Date of printing: 11/03/20
	N 10: STABILITY AND R	EACTIVITY			
10.1	REACTIVITY:				
	- Corrosivity to meta	ls:			
	It is not corrosive to me	etals.			
	- Pyrophorical prope	<u>rties:</u>			
	It is not pyrophoric.				
0.2	CHEMICAL STABILI				
0.0	Stable under recommended storage and ha				
0.3		action with oxidizing agent			
0.4	CONDITIONS TO AV				
0.1	- Heat:				
	Keep away from source	es of heat.			
	- Light:				
	If possible, avoid direct	contact with sunlight.			
	<u>- Air:</u>				
		cted by exposure to air, bu	it should not be left the containers	s open.	
	<u>- Pressure:</u> Not relevant.				
	- Shock:				
		sitive to shocks, but as a re	ecommendation of a general natu	ire should be avoided humps	and rough handling to ave
			en the product is handled in large		
).5	INCOMPATIBLE MA	TERIALS:			
		ing agents, acids, alkalis.			
0.6		MPOSITION PRODUC			
	As consequence of the halogenated compound		rdous products may be produced	l: nitrogen oxides, sulfur oxide	es, hydrochloric acid,
	N 11: TOXICOLOGICAL				
			preparation is available. The to	vicele ricel close if in the for	
1.1			tion method of the Regulation	. ,	692 (CLP).
				(20) 110 1212/2000.	
	ACUTE TOXICITY:				
	Dose and lethal conc		DL50 (OECD401)	DL50 (OECD402	
	Dose and lethal conc for individual ingredie	nts:	DL50 (OECD401) mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous	s mg/m3·4h Inhalat
	Dose and lethal conce for individual ingredie 1,2-benzisothiazol-3(2	nts: 2H)-one	DL50 (OECD401) mg/kg bw Ora 490 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3(2 Reaction mass of 5-c isothiazolin-3-one [EC	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2-	DL50 (OECD401) mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3(2 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol-	nts: 2H)-one hloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora 490 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
	Dose and lethal conce for individual ingredie 1,2-benzisothiazol-3(2 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1)	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6]	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra	s mg/m3·4ȟ Inhalat t t > 1230 I
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra	s mg/m3·4h Inhalat t t > 1230 l t > 2050 l
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3 Estimates of acute to	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE)	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra ATE	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra	s mg/m3·4h Inhalat t t > 1230 l t > 2050 l =A
	Dose and lethal conce for individual ingredie 1,2-benzisothiazol-3(2 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(2 Estimates of acute to for individual ingredie	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts:	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra ATE mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra > 2000 Ra ATE mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t > 1230 l t > 2050 l =A
	Dose and lethal conce for individual ingredie 1,2-benzisothiazol-3(2 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(2 Estimates of acute to for individual ingredie 1,2-benzisothiazol-3(2	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 1020 Rat 1020 Rat ATE mg/kg bw Ora 490	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t t > 1230 l t > 2050 l s mg/m3·4h Inhalat
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3( Estimates of acute to for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra ATE mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t t > 1230 l t > 2050 l s mg/m3·4h Inhalat
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3( Estimates of acute to for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [EC	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 1020 Rat 1020 Rat ATE mg/kg bw Ora 490	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t t > 1230 l t > 2050 l s mg/m3·4h Inhalat
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3( Estimates of acute to for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [EC	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2-	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 1020 Rat 1020 Rat ATE mg/kg bw Ora 490	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous	s mg/m3·4h Inhalat t > 1230 F t > 2050 F t > 2050 F S mg/m3·4h Inhalat
	Dose and lethal conce for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3 Estimates of acute to for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra MTE mg/kg bw Ora 490 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra 2000 Ra ATE mg/kg bw Cutaneous 140	s mg/m3·4h Inhalat t > 1230 l t > 2050 l s mg/m3·4h Inhalat - *>
	Dose and lethal concerns         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         For individual ingredie         1,2-benzisothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         (3:1)         1,2-benzisothiazol-3(3         (3:1)         1,2-benzisothiazol-3(3         (*) - Point estimates of be used in the calculati	nts: 2H)-one hloro-2-methyl-2H- 2 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- 2 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one acute toxicity correspondition on of the ATE for classification	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra ATE mg/kg bw Ora 490 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra 2000 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe	s mg/m3·4h Inhalat t > 1230 I t > 2050 I s mg/m3·4h Inhalat o *> - hese values are designed ent test results.
	Dose and lethal conce for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3 For individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3 (*) - Point estimates of be used in the calculati (-) - The components th	nts: 2H)-one hloro-2-methyl-2H- 2 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- 2 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one acute toxicity correspondit on of the ATE for classifica nat are assumed to have n	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra MTE mg/kg bw Ora 490 74,9 *567 ng to the classification category ( ation of a mixture based on its co	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra 2000 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe shold of category 4 for the cor	s mg/m3·4h Inhalat t > 1230 l t > 2050 l s mg/m3·4h Inhalat A mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout NOAEC Inhalat
	Dose and lethal conc for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3 Festimates of acute to for individual ingredie 1,2-benzisothiazol-3(3 Reaction mass of 5-c isothiazolin-3-one [EC methyl-2H-isothiazol- (3:1) 1,2-benzisothiazol-3(3 (*) - Point estimates of be used in the calculati (-) - The components th are ignored.	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one acute toxicity correspondin on of the ATE for classification and are assumed to have not an	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra 1020 Ra MTE mg/kg bw Ora 490 74,9 *567 ng to the classification category ( ation of a mixture based on its co to acute toxicity at the upper three	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represent shold of category 4 for the cor MOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t > 1230 l t > 2050 l s mg/m3·4h Inhalat A mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout NOAEC Inhalat
	Dose and lethal concerned for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         1,2-benzisothiazol-3(3         (*) - Point estimates of be used in the calculati         (-) - The components the are ignored.         - No observed adverse         1,2-benzisothiazol-3(3         - Lowest observed adverse         Not available	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one acute toxicity corresponding on of the ATE for classification and are assumed to have not be effect level 2H)-one dverse effect level	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra ATE mg/kg bw Ora 490 74,9 *567 ng to the classification category ( ation of a mixture based on its co to acute toxicity at the upper three NOAEL Ora mg/kg bw/d	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe shold of category 4 for the con MOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t > 1230 f t > 2050 f s mg/m3·4h Inhalat A mg/m3·4h Inhalat bese values are designed ont test results. rresponding exposure rout NOAEC Inhalat
	Dose and lethal concerned for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Estimates of acute to:         for individual ingredie         1,2-benzisothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         Reaction mass of 5-c         isothiazolin-3-one [EC]         methyl-2H-isothiazol-3(3         1,2-benzisothiazol-3(3         (*) - Point estimates of be used in the calculati         (-) - The components the are ignored.         - No observed adverse         1,2-benzisothiazol-3(3         - Lowest observed adverse         Not available	nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one xicity (ATE) nts: 2H)-one hloro-2-methyl-2H- C 247-500-7] and 2- 3-one [EC 220-239-6] 2H)-one acute toxicity corresponding on of the ATE for classification and are assumed to have not be effect level 2H)-one dverse effect level	DL50 (OECD401) mg/kg bw Ora 490 Ra 74,9 Ra 1020 Ra 1020 Ra MTE mg/kg bw Ora 490 74,9 *567 ng to the classification category ( ation of a mixture based on its co to acute toxicity at the upper three NOAEL Ora mg/kg bw/d 69 Ra	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra > 2000 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe shold of category 4 for the con MOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t t > 1230 F s 2050 F s mg/m3·4h Inhalat o *> hese values are designed ent test results. rresponding exposure rout s NOAEC Inhalat mg/



DUEPOL ACQUA SUELOS SATINADO

s Code : 1656

Version: 3	Revision: 11/03/2024	Previ	ious revision: 23/12/2022	Date of printing:	11/03/2024
Skin: Not classified	ATE > 5000 mg/kg bw		Not classified as a product wi in contact with skin (based on the classification criteria are r	available data,	
Eyes: Not classified	Not available.		Not classified as a product wi by eye contact (lack of data).		GHS/CLP 1.2.5.
Ingestion: Not classified	ATE > 5000 mg/kg bw		Not classified as a product wi if swallowed (based on availa classification criteria are not r	ble data, the	GHS/CLP 3.1.3.6.

GHS/CLP 3.1.3.6: Classification of mixtures based on ingredients of the mixture (additivity formula).

## CORROSION / IRRITATION / SENSITISATION :

Danger class	Target organs	Cat.	Main effects, acute and/or delayed	Criteria
<ul> <li>Respiratory corrosion/irritation: Not classified</li> </ul>	-	-	Not classified as a product corrosive or irritant by inhalation (based on available data the classification criteria are not met).	GHS/CLP ,1.2.6. 3.8.3.4.
- Skin corrosion/irritation: Not classified	-	-	Not classified as a product corrosive or irritant in contact with skin (based on available data, the classification criteria are not met).	GHS/CLP 3.2.3.3.
- Serious eye damage/irritation: Not classified	-	-	Not classified as a product corrosive or irritant in contact with eyes (based on available data, the classification criteria are not met).	GHS/CLP 3.3.3.3.
<ul> <li>Respiratory sensitisation: Not classified</li> </ul>	-	-	Not classified as a product sensitising by inhalation (based on available data, the classification criteria are not met).	GHS/CLP 3.4.3.3.
- Skin sensitisation: Not classified	-	-	Not classified as a product sensitising by skin contact (based on available data, the classification criteria are not met).	GHS/CLP 3.4.3.3.

GHS/CLP 3.2.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.3.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.4.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components.

## - ASPIRATION HAZARD:

Danger class	Target organs	Cat.	Main effects, acute and/or delayed	Criteria
- Aspiration hazard: Not classified	-			GHS/CLP 3.10.3.3.

GHS/CLP 3.10.3.3: Classification of the mixture when data are available for all components or only for some components.

<u>SPECIFIC TARGET ORGANS TOXICITY (STOT): Single exposure (SE) and/or Repeated exposure (RE):</u> Not classified as a dangerous product for target organs.

GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components.

CMR EFFECTS:

- Carcinogenic effects:

It is not considered as a carcinogenic product.

- Genotoxicity:

It is not considered as a mutagenic product.

Toxicity for reproduction:

Does not harm fertility.Does not harm the unborn child.

- Effects via lactation:

Not classified as a hazardous product for children breast-fed.

DELAYED AND IMMEDIATE EFFECTS AS WELL AS CHRONIC EFFECTS FROM SHORT AND LONG-TERM EXPOSURE: Routes of exposure Not available. - Short-term exposure: # Causes skin irritation. Causes serious eye damage. May cause respiratory irritation. May cause drowsiness or dizziness. - Long-term or repeated exposure: Not available.

	,		lation (EU) No. 2020/878		(Language:E
	DUEPOL AC Code : 1656	QUA SUE	LOS SATINADO		
ersion: 3 Rev	vision: 11/03/	2024	Previou	s revision: 23/12/2022	Date of printing: 11/03/202
INTERACTIVE EFFE	ECTS:				
Not available.					
INFORMATION ABC	<u>) UT TOXICO</u>		S, METABOLISM AND DISTRIBUTI	<u>ON:</u>	
- Dermal absorption	•				
Not available. - Basic toxicokinetic	·c.				
Not available.	<u>o.</u>				
ADDITIONAL INFOR Not available.	<u>KIVIATION:</u>				
1.2 INFORMATION ON	OTHER HAZ	ARDS:			
Endocrine disrupting					
This product does not Other information:	contain substa	nces with	endocrine disrupting properties identifie	ed or under evaluation.	
No additional informati	ion available.				
ECTION 12: ECOLOGICAL INF	ORMATION				
# No experimental e	cotoxicologica	l data on	the preparation as such is available	e. The ecotoxicological cla	assification for these
mixture has been can (CLP).	rried out by us	sing the c	onventional calculation method of th	ne Regulation (EU) No. 12	272/2008~2022/692
- Acute toxicity in aqu		nent	CL50 (OECD 203)	CE50 (OECD 202)	CE50 (OECD 20
for individual ingredie			mg/I·96hours	mg/l·48hours	mg/l·72hou
1,2-benzisothiazol-3( Reaction mass of 5-c	· /		2.2 - Fishes 0.19 - Fishes	2.9 - Daphniae 0.16 - Daphniae	0.11 - Alga 0.037 - Alga
isothiazolin-3-one [E	C 247-500-7]	and 2-		0.10 - Daprinae	0.037 - Alg
methyl-2H-isothiazol	-3-one [EC 22	0-239-6]			
(3:1) 1,2-benzisothiazol-3(	(2H)-one		1.2 - Fishes	0.85 - Daphniae	0.37 - Alg
1,2-00121301110201-0(			1.2 - 1 151105	0.00 - Daprinac	0.07 - 749
- No observed effect	concentration	1	NOEC (OECD 210) mg/l · 28 days	NOEC (OECD 211) mg/l · 21 days	NOEC (OECD 20 mg/l · 72 hou
1,2-benzisothiazol-3(	(2H)-one		mg/r 20 days	ing/i 21 days	0.04 - Alga
Reaction mass of 5-c			0.02 - Fishes	0.011 - Daphniae	0.004 - Alga
isothiazolin-3-one [E0 methyl-2H-isothiazol-					
(3:1)		.0 200 0]			
			· · ·		
- Lowest observed en Not available	ffect concentra	ation			
ASSESSMENT OF A		XICITY:			
		Cat.	Main hazards to the aquatic environme	ent	Criteria
Aquatic toxicity					
			Not classified as a bazardous product	with acute toxicity to aquatic	
Aquatic toxicity - Acute aquatic toxicit Not classified			Not classified as a hazardous product (based on available data, the classifica		c life GHS/CLP 4.1.3.5.5.3.
- Acute aquatic toxicit	ty:	-	(based on available data, the classifica Not classified as a dangerous product	ation criteria are not met). with chronic toxicity to aqua	4.1.3.5.5.3. atic life GHS/CLP
- Acute aquatic toxicit Not classified	ty:	-	(based on available data, the classifica	ation criteria are not met). with chronic toxicity to aqua	4.1.3.5.5.3. atic life GHS/CLP
<ul> <li>Acute aquatic toxicit</li> <li>Not classified</li> <li>Chronic aquatic toxi</li> </ul>	ty: icity:	-	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met).	ation criteria are not met). with chronic toxicity to aqua ilable data, the classificatior	4.1.3.5.5.3. atic life GHS/CLP
<ul> <li>Acute aquatic toxicit</li> <li>Not classified</li> <li>Chronic aquatic toxi</li> <li>CLP 4.1.3.5.5.3: Class</li> </ul>	ty: icity: sification of a m	- ixture for a	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components.	4.1.3.5.5.3. atic life GHS/CLP n criteria 4.1.3.5.5.4.
<ul> <li>Acute aquatic toxicit Not classified</li> <li>Chronic aquatic toxi</li> <li>CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class</li> </ul>	ty: icity: sification of a m sification of a m	- ixture for a ixture for c	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met).	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components.	4.1.3.5.5.3. atic life GHS/CLP n criteria 4.1.3.5.5.4.
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class     CLP 4.1.3.5.5.4: Class 2.2 PERSISTENCE ANE	ty: icity: sification of a m sification of a m	- ixture for a ixture for c	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components.	4.1.3.5.5.3. atic life GHS/CLP n criteria 4.1.3.5.5.4.
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE AND     Biodegradability:	ty: icity: sification of a m sification of a m	- ixture for a ixture for c	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components.	4.1.3.5.5.3. atic life GHS/CLP n criteria 4.1.3.5.5.4.
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE AND     - Biodegradability: Not available. Aerobic biodegradati	ty: icity: sification of a m sification of a m D DEGRADAE	- ixture for a ixture for c	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO	4.1.3.5.5.3. atic life GHS/CLP n criteria 4.1.3.5.5.4.
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE AND     - Biodegradability: Not available. Aerobic biodegradati for individual ingredie	ty: icity: sification of a m sification of a m D DEGRADAE ion ents	- ixture for a ixture for c	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com	4.1.3.5.5.3. atic life GHS/CLP 4.1.3.5.5.4. nponents. Biodegradabilid
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class     CLP 4.1.3.5.5.4: Class     DERSISTENCE AND     - Biodegradability: Not available.     Aerobic biodegradati for individual ingredie 1,2-benzisothiazol-3(	ty: icity: sification of a m sification of a m D DEGRADAE ion ents (2H)-one	- ixture for a ixture for o	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO 5 days 14 days 28 days 	4.1.3.5.5.3. atic life GHS/CLP 4.1.3.5.5.4. nponents. Biodegradabilid
<ul> <li>Acute aquatic toxicit Not classified</li> <li>Chronic aquatic toxi</li> <li>CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class</li> <li>2.2 PERSISTENCE AND - Biodegradability: Not available.</li> <li>Aerobic biodegradati for individual ingredice</li> </ul>	ty: icity: sification of a m sification of a m D DEGRADAE D DEGRADAE (2H)-one chloro-2-methy	- ixture for a ixture for o BILITY: yl-2H-	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO	4.1.3.5.5.3. atic life GHS/CLP 4.1.3.5.5.4. nponents. Biodegradabilid
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class CLP 4.1.3.5.5.4: Class 2.2     PERSISTENCE ANE     - Biodegradability: Not available. Aerobic biodegradati for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-co isothiazolin-3-one [E0 methyl-2H-isothiazol-	ty: icity: icity: isification of a m ification of a m D DEGRADAE D DEGRADAE ion ents (2H)-one chloro-2-meth C 247-500-7]	- ixture for a ixture for o BILITY: yl-2H- and 2-	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO 5 days 14 days 28 days 	4.1.3.5.5.3. atic life GHS/CLP 4.1.3.5.5.4. nponents. Biodegradabilid
Acute aquatic toxicit Not classified     Chronic aquatic toxic CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class CLP 4.1.3.5.5.4: Class 2.2 PERSISTENCE AND <u>- Biodegradability:</u> Not available. Aerobic biodegradatii for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [Eo methyl-2H-isothiazol- (3:1)	ty: icity: icity: ification of a m sification of a m D DEGRADAE D DEGRADAE ion ents (2H)-one chloro-2-methy C 247-500-7] -3-one [EC 22	- ixture for a ixture for o BILITY: yl-2H- and 2-	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO 5 days 14 days 28 days 	4.1.3.5.5.3. atic life GHS/CLP 4.1.3.5.5.4. ponents. Biodegradabilid Not ea Not ea
Acute aquatic toxicit Not classified     Chronic aquatic toxic CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class CLP 4.1.3.5.5.4: Class 2.2 PERSISTENCE ANE - Biodegradability: Not available. Aerobic biodegradatil for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [E4 methyl-2H-isothiazol-3( (3:1) 1,2-benzisothiazol-3(	ty: icity: isification of a m sification of a m D DEGRADAE D DEGRADAE ion ents (2H)-one chloro-2-methy C 247-500-7] -3-one [EC 22 (2H)-one	- ixture for a ixture for o <u>3ILITY:</u> yl-2H- and 2- 20-239-6]	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO 5 days 14 days 28 days 55 55	4.1.3.5.5.3. atic life GHS/CLP 4.1.3.5.5.4. nponents. Biodegradabilid
Acute aquatic toxicit Not classified     Chronic aquatic toxi     CLP 4.1.3.5.5.3: Class CLP 4.1.3.5.5.4: Class CLP 4.1.3.5.5.4: Class     CLP 4.1.3.5.5.4: Class     CLP 4.1.3.5.5.4: Class     Acrobic biodegradability: Not available. Aerobic biodegradatil for individual ingredie 1,2-benzisothiazol-3( Reaction mass of 5-c isothiazolin-3-one [E0] methyl-2H-isothiazol-3( (3:1) 1,2-benzisothiazol-3(	ty: icity: isification of a m sification of a m D DEGRADAE D DEGRADAE ion ents (2H)-one chloro-2-methy C 247-500-7] -3-one [EC 22 (2H)-one	- ixture for a ixture for o <u>3ILITY:</u> yl-2H- and 2- 20-239-6]	(based on available data, the classifica Not classified as a dangerous product with long lasting effects (based on avai are not met). acute hazards, based on summation of chronic (long term) hazards, based on s	ation criteria are not met). with chronic toxicity to aqua ilable data, the classification classified components. summation of classified com %DBO/DQO 5 days 14 days 28 days 55 55	4.1.3.5.5.3. atic life GHS/CLP h criteria 4.1.3.5.5.4. nponents. Biodegradabilid Not ea Not ea

Photodegradability: Not available.      Bioaccumulation     IogPow     BCF     Poi     Decommulation     IogPow     BCF     Poi     Decommulation     IogPow     IogPow     BCF     Poi     Decommulation     IogPow	Printers     Code: 1956      Previous revision: 2012/2022     Date of printing: 1103/2024     Previous revision: 2012/2022     Date of printing: 1103/20     Previous revision: 2012/2022     Unikely, 1     Prevision: 2012/2023/2014/201     Unikely, 1     Prevision: 2012/2023/2014/201     Unikely, 1     Prevision: 2012/2013/2014/2014     Prevision: 2012/2014/2014     Prevision: 2012/2014/2014/2014/2014/2014/2014/2014/	accorda	Y DATA SHEET (F ance with Regulation (EC	C) No. 1907/2006 a	nd Regulation (	EU) No. 2020/878		(Language:E		
Photodegradability:     Not available     Bioaccumulation     Bioaccumulatin     Bioaccumulation     Bioaccumulation     Bioaccumulation	- Photodegradability: Not available.       Not available.         12.3       BIOACCUMULATIVE POTENTIAL: Not available.       IogPow       BIOACCUMULATIVE POTENTIAL: Not available.         12.4       BIOACCUMULATIVE POTENTIAL: Not available.       IogPow       BIOACCUMULATIVE POTENTIAL: Not available.         12.5       BIOACCUMULATIVE POTENTIAL: Not available.       IogPow       BIOACCUMULATIVE POTENTIAL: Not available.         12.4       Motification-3-one [EC 247-500-7] and 2- prestly-i241-isothiazol-3-one [EC 220-239-6] (3:1)       I.2.5-enzisothiazol-3-one [EC 220-239-6] (3:1)       Unlikely. I         12.4       Mot available       Iog Poc Penzisothiazol-3-One [EC 247-500-7] and 2- prestly-i241-isothiazol-3-One [EC 220-239-6] (3:1)       Unlikely. I         12.4       Not available       Iog Poc Penzisothiazol-3(2H)-one       0.97       Unlikely. I         Not available       IogPoc Penzisothiazol-3(2H)-one       0.97       Unlikely. I         12.5       RESULTS OF PBT AND VPV8 ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PBT//PVB criteria.       Unlikely. I         12.6       ENDOCINE DISRUPTINES POPPETIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       O11FER ADVERSE EFFECTIS: -0.20ne depletion potential: Not available. -Photochemical coone creation potential: Not available. -Photochemical coone creation potential: Not available. -Photochemical coone creation potential: Not availabl	К	isaval		UA SUELOS S/	ATINADO				
Not available.           12.3         BIOACCUMULATIVE POTENTIAL: Not available.           BIOACCUMULATIVE POTENTIAL: Not available.         IogPow         BCF         Pol           Live         O.7         6.62 (calculated)         Unlikel           Reaction mass of 5-chloro-2-methyl-2H.         0.7         3.2 (calculated)         Unlikel           Reaction mass of 5-chloro-2-methyl-2H.         0.75         3.2 (calculated)         Unlikel           sothiazolin-3-one [EC 220-239-6]         (31)         1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           Mobility         Incertain to fill the provide t	Not available.           [2:3]         BIGACCUMULATIVE POTENTIAL: Not available.           [3:1]         Not available.           [1:2-benzisothiazol-3(2H)-one         0.7           [3:1]         Reaction mass of 5-chloro-2-methyl-2H- sothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         0.75           [3:1]         1:2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.97         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.97         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         0.97         Unlikely, I           [3:1]         1:2-benzisothiazol-3(2H)-one         1.05         Unlikely, I           [2:5]         RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006:)         Des not contain substances with endocrine disrupting properties identified or under evaluation.           [2:6]         RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006:)         Des not contain substances with endocrine disrupting properties identi	ersior	n: 3 Re	evision: 11/03/20	)24	Prev	ious revision: 23/12/2022	Date of printing: 11/03/202		
12.3       BIOACCLIMULATIVE POTENTIAL: Not available.         Bioaccumulation for individual ingredients       logPow       BCF LAQ         12-benzisothiza/3.2N=One       0.7       6.62 (calculated)       Unlikel sothizazion-3-one [EC 247-500-7] and 2.         statisztim-3-one [EC 247-500-7] and 2.       0.75       3.2 (calculated)       Unlikel         sothizazion-3-one [EC 247-500-7] and 2.       0.64       3.2 (calculated)       Unlikel         12-benzisothiza/0-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility for individual ingredients       log Poc       Constant of Henry PamSmo 27C       Pol         12-benzisothiza/0-3(2H)-one       0.97       Vanikel       Unlikel         sothizabiliza/0-3(2H)-one       0.97       Vanikel       Unlikel         sothiza/oin-3-one [EC 247-500-7] and 2.       0.45       Unlikel         sothizabiliza-0-3(2H)-one       1.05       Unlikel         12-benzisothiza-0-3(2H)-one	12.3       BIOACCUMULATIVE POTENTIAL: Not available.         Not available.       Bioaccumulation individual ingredients       logPow       BCF       Poten         12.5enzisothiazol-3(2H)-one       0.7       6.62 (calculated)       Unlikely, I         sothiazolin-3-one [EC 220-239-6]       3.2 (calculated)       Unlikely, I         31       12.5enzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         12.4       MOBILITY IN SOIL: Not available       0.64       3.2 (calculated)       Unlikely, I         12.4       Not available       0.64       3.2 (calculated)       Unlikely, I         12.5       Reaction mass of 5-chloro-2-methyl-2H- sothiazol-3(2H)-one       0.97       Poten       Poten         12.5       RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006.)       Does no contain substances that fulfil the PBT/VPB criteria.       ENDOCRINE DISRUETING PROPERTIES: This product does not contain substances that fulfil the PBT/VPB criteria.       ENDOCRINE DISRUETING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       OTHER ADVERSE EFFECTS: -0.20ne depletion potential: Not available.       -0.20ne depletion potential: Not available.			<u>/:</u>						
Not available.           Bioaccumulation         logPow         BCF         Pol           L2-benzisofilizzol-3(2H)-one         0.7         6.62 (calculated)         Unlikel           Reaction mass of 5-choro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikel           3(1)         1_2-benzisofiliazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           MoBility         log Poc         Constant of Henry Pamämo 27C         Pol           Mot available         0.97         Unlikel         Unlikel           Mobility in stoluzol-3(2H)-one         0.97         Unlikel           Reaction mass of 5-choro-2-methyl-2H- isothiazolin-3one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-238-6] (3:1)         Unlikel         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel         Unlikel           Resection mass of 5-choro-2-methyl-2H- isothiazol-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05         Unlikel           1_2-benzisothiazol-3(2H)-one         1.05<	Not available.           Bioaccumulation for individual ingredients         logPow         BCF         Poten           1.2-benzisofhiazol-3(2H)-one         0.7         6.62 (calculated)         Unlikely, I           Reaction mass of 5-chloro-2-methyl-2H- sothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3-one [EC 220-239-6]         0.64         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           MoBility for individual ingredients         log Poc Por matively Pam3inol 20°C         Poten           1.2-benzisothiazol-3(2H)-one         0.97         Constant of Henry Pam3inol 20°C         Poten           1.2-benzisothiazol-3(2H)-one         0.97         Unlikely, I         unlikely, I           1.2-benzisothiazol-3(2H)-one         1.05         Unlikely, I           1.3:1         1.2-benzisothiazol-3(2H)-one         1.05         Unlikely, I           1.2:6         RESULTS OF PBT AND VEVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006.)         Does not contain substances with endocrine disrupting properties identified or under evaluation.           1:7         OTHER ADVERSE EFFECTS:         .         Ozone depletion potential: Not available.           1:7<	2.3		F POTENTIAL :						
Ici         Ici         Ici           12-benzisothiazol-3(2H)-one         0.7         6.62 (calculated)         Unlikel           Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           (3:1)         1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikel           Not available         0.97         Pol         Pol           Not available         0.97         Unlikel         Not available           Not available         0.97         Unlikel         Not available         Unlikel           Reaction mass of 5-chloro-2-methyl-2H- sothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         1.05         Unlikel           12-benzisothiazol-3(2H)-one         1.05         Unlikel         Unlikel           13-1         Reaction mass of 5-chloro-2-methyl-2H- sothiazol-3(2H)-one         1.05         Unlikel           12-6         RESULTS OF PBT AND VPVB ASESEMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)         <	for individual ingredients         Use           1.2-benzisothiazol-3(2H)-one         0.7         6.62 (calculated)         Unlikely, I           Reaction mass of 5-chlore-2-methyl-2H- isothiazoli-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         0.75         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           1.2-benzisothiazol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           Not available         Not available         Not available         Not available           Mobility         log Pod         Constant of Henry Pam3tm0 20°C         Poten Pam3tm0 20°C         Poten Pam3tm0 20°C         Poten Pam3tm0 20°C         Unlikely, I           I.2-benzisothiazol-3(2H)-one         0,97         Unlikely, I         Unlikely, I         Sothiazoli-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         1,05         Unlikely, I           1.2-benzisothiazol-3(2H)-one         1,05         Unlikely, I         Sothiazol-3(2H)-one         1,05           1.2-benzisothiazol-3(2H)-one         1,05         Unlikely, I         Sothiazol-3(2H)-one         1,05           1.2-benzisothiazol-3(2H)-one         1,05         Unlikely, I         Sothiazol-3(2H)-one         1,05           1.2-benzisothiazol-3(2H)-one         1,05 </td <td>12.0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	12.0								
12.2benzisothiazol-3(2H)-one       0.7       6.62 (calculated)       Unlikel         Reaction mass of 5-chloro-2-methyl-2H-       0.75       3.2 (calculated)       Unlikel         sothiazol-3-QH)-one       0.64       3.2 (calculated)       Unlikel         (3:1)       12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility       12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility       for individual ingredients       10g Poc       Constant of Henry       Pol         Mobility       for individual ingredients       0.97       Unlikel       Unlikel         Reaction mass of 5-chloro-2-methyl-2H-       0.45       Unlikel       Unlikel         sothiazol-3(2H)-one       1.05       Unlikel       Unlikel         12-benzisothiazol-3(2H)-one       1.05       Unlikel       Unlikel         12-benzisothiazol-3(2H)-one       1.05       Unlikel         12.6       ENDCCRNE DISRUPTING PROPERTIES:       This product does not contain substances with endocrine disrupting properties identified or under evaluation.       10.7         12.7       OTHER ADVERSE EFFECTS:       - Ozone depletion potential:       Not available.       - Potochemical azone creation potential:         Not available.       - Potochet	12-Henzisofhiazol-3(2H)-one       0.7       6.62 (calculated)       Unlikely, I         Reaction mass of 5-chloro-2-methyl-2H.       0.75       3.2 (calculated)       Unlikely, I         softiazoln-3-one [EC 220-239-6]       0.75       3.2 (calculated)       Unlikely, I         (3:1)       12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         12-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         Not available       0       0.64       3.2 (calculated)       Unlikely, I         Not available       0       90       Poten       Par.Mon.200C       Poten         Not available       0.97       Constant of Henry       Poten       Poten       Par.Mon.200C       Unlikely, I         12-benzisothiazol-3(2H)-one       0.97       Unlikely, I       Unlikely, I       Unlikely, I       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I       Unlikely, I       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I         12-benzisothiazol-3(2H)-one       1.05       Unlikely, I			-		logPow				
Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikel           (3:1)         1,2-benzisothiazol-3-one [EC 220-239-6]         0.64         3.2 (calculated)         Unlikel           Not available         0.64         3.2 (calculated)         Unlikel           MOBILITY IN SOIL: Not available         0.64         3.2 (calculated)         Unlikel           Mobility for individual ingredients         0.97         Perm3mol 29°C         Poil           I_2-benzisothiazol-3(2H)-one         0.97         Unlikel         Unlikel           Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3.1)         1.05         Unlikel           12.5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006): Does not contain substances with endocrine disrupting properties identified or under evaluation.         1.05           12.6         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         1.07           12.7         OTHER ADVERSE EFFECTS: - Ozone depletion potential; Not available: - Earthi dobal warming potential; Not available: - Earth idoba	Reaction mass of 5-chloro-2-methyl-2H- bothizzolin-3-one [EC 247-500-7] and 2- methyl-2H-isothizzoli-3-one [EC 220-239-6]         0.75         3.2 (calculated)         Unlikely, I           (3:1)         12-benzisothizzol-3(2H)-one         0.64         3.2 (calculated)         Unlikely, I           12.4         MOBILITY IN SOIL. Not available         0.64         3.2 (calculated)         Unlikely, I           12.4         MOBILITY IN SOIL. Not available         0.97         Constant of Henry Pa-m3/mol 20°C         Poten           12.4         MOBILITY IN SOIL. Not available         0.97         Unlikely, I         Unlikely, I           12-benzisothizazol-3(2H)-one         0.97         Unlikely, I         Unlikely, I           12-benzisothizazol-3-one [EC 247-500-7] and 2- methyl-2H-isothizazol-3-one [EC 247-500-7] and 2- methyl-2H-isothizazol-3-one [EC 247-500-7] and 2- methyl-2H-isothizazol-3-One [EC 220-8]         Unlikely, I           12-5         RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.) Does not contain substances that fulfi the PBT/VPVB criteria.         DocCNINE DISRUPTING PMCPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.		<b>Ç</b>			0.7		5		
isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6]       Initiazolin-3-one [EC 220-239-6]         [1,2-benzisothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikel         Mobility       Iog Poc       Constant of Henry       Pol         Not available       0.97       Para3mot 20°C       Unlikel         Iz-benzisothiazol-3(2H)-one       0.97       Unlikel       Iog Poc       Status 20°C         1,2-benzisothiazol-3(2H)-one       0.97       Unlikel       Ionizolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one       1,05       Unlikel         1,2-benzisothiazol-3(2H)-one       1,05       Unlikel       Ionizolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one       1,05       Unlikel         12.5       RESULTS OF PET AND VPVB ASSESMENT (Annex XIII of Regulation (EC) no. 1907/2006.)       Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:       This product does not contain substances with endocrine disrupting properties identified or under evaluation.       .         12.7       OTHER ADVERSE EFFECTS:       -       -       -         .       -Drotochemical ozone creation potential:       Not available.       .         .       -Pholochemical ozone creation potential:       Not available.       .         . <td>isothiazolin3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL; Not available       Iog Pod Poten       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL; Not available       Iog Pod Poten       Constant of Henry       Poten         [3.1]       I_2-benzisothiazol-3(2H)-one       0.97       Unlikely, I         [3.2]       Reaction mass of 5-chloro-2-methyl-2H- isothiazolin3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one       0.97       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.2]       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.)       Does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.6]       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.7]       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.       -Description       101         [3.1]       MASET TRRATMENT METHODS: Directive 2008/98/EC-Regulation (</td> <td></td> <td></td> <td>· /</td> <td>211</td> <td></td> <td></td> <td>,</td>	isothiazolin3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL; Not available       Iog Pod Poten       0.64       3.2 (calculated)       Unlikely, I         [2.4       MOBILITY IN SOIL; Not available       Iog Pod Poten       Constant of Henry       Poten         [3.1]       I_2-benzisothiazol-3(2H)-one       0.97       Unlikely, I         [3.2]       Reaction mass of 5-chloro-2-methyl-2H- isothiazolin3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one       0.97       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.1]       I_2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         [3.2]       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.)       Does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.6]       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       101         [2.7]       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.       -Description       101         [3.1]       MASET TRRATMENT METHODS: Directive 2008/98/EC-Regulation (			· /	211			,		
12.4       MOBILITY IN SOIL: Not available       Iog Pod Constant of Henry Parm3/mol 20°C       Pot Parm3/mol 20°C         Mobility for individual ingredients       Iog Pod Constant of Henry Parm3/mol 20°C       Pot         Reaction mass of 5-chloro-2-methyl-2H- isothiazol-3-(2H)-one Reaction mass of 5-chloro-2-methyl-2H- isothiazol-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)       Unlikel         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PBT/vPvB criteria.       Unlikel         12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       IOTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.         Photochemical ozone creation potential: Not available.       Earth global warming potential: Not available.       Batochemical ozone creation potential: Not available.         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers: And packaging should be disposed in accordance with current local	12.4       MOBILITY IN SOIL: Not available       Not available         MOBILITY IN SOIL: Not available       Iog Poc       Constant of Henry Pam3/mol 20°C       Poten         1,2-benzisothiazol-3(2H)-one       0,97       Unlikely, I         Reaction mass of 5-chloro-2-methyl-2H- isothiazoli-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)       Unlikely, I         1,2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PBT/VPB or iteria.       Iunlikely, I         12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       Iunlikely, I         12.7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.       - Denochemical ozone creation potential: Not available.       - Earth global warming potential; Not available.         13.1       Take all necessary measures to prevent the production of waste whenever possible, Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controis and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers: Directive 94/62/EC~2015/720/EU, Decision 2000/		isothiazolin-3-one [E methyl-2H-isothiazo	EC 247-500-7] ar	nd 2-	0.75	3.2 (Calculate	ea) Onlikely, lo		
Not available           Mobility         Iog Poc         Constant of Henry Pa:m3/mol 20°C         Pol           1,2-benzisothiazol-3(2H)-one         0,97         Unlikel           Reaction mass of 5-chloro-2-methyl-2H- isothiazol-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3(2H)-one         1,05         Unlikel           12-5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006;) Does not contain substances that fulfil the PBT/vPvB criteria.         100         100           12-6         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         112.7         OTHER ADVERSE EFFECTS: Ozone depletion potential: Not available.        Denotencial coone creation potential: Not available.        Photochemical ozone creation potential: Not available.         Not available.           13.1         WASTE TREATMENT METHODS:Directive 2008/98/ECRegulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.           LER code         Description         Type of waste           Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers	Not available         Iog Poc         Constant of Henry Parm3/mol 20°C         Poten           1,2-benzisothiazol-3(2H)-one         0,97         Unlikely, 1           Reaction mass of 5-chioro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)         Unlikely, 1           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, 1           22.6         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)         Does not contain substances that fulfil the PBT/vPvB criteria.           12.6         ENDOCRINE DISRUPTING PROPERTIES:         This product does not contain substances with endocrine disrupting properties identified or under evaluation.         10           12.7         OZnene depletion potential: Not available.         -         -           - Photochemical zone creation potential: Not available.         -         Not available.         -           - SCONN 13: DISPOSAL CONSIDERATIONS         If the antherose matherose mathero		1,2-benzisothiazol-3	B(2H)-one		0.64	3.2 (calculate	ed) Unlikely, lo		
Mobility for individual ingredients         log Pod for individual ingredients         Pod Parm3/mol 20°C           12-benzisothiazol-3(2H)-one         0,97         Unlikel           Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 239-6] (3:1)         0,45         Unlikel           12-5         RESULTS OF PBT AND VPVB ASSESMENT.(Annex XIII of Regulation (EC) no. 1907/2006.)         Unlikel           Does not contain substances that fulfil the PBT/VPVB criteria.         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7           OTHER ADVERSE EFFECTS: -Ozone depletion potential: Not available.         -Ozone depletion potential: Not available.         Not available.           ECTION 13: DISPOSAL CONSIDERATIONS         Usate should be product does for revaluation of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.           LER code         Description         Type of waste           Disposal of empty containers.Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU.         # Emptied containers and packaging should be disposed in accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8. <t< td=""><td>Mobility         log Pod for individual ingredients         log Pod for individual ingredients         Poten Para3/mol 20°C           1, 2-benzisothiazol-3(2H)-one         0,97         Unlikely, I           Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)         Unlikely, I         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           Does not contain substances that fulfil the PBT/VPVB criteria.         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         Indix 201-202-202-202-202-202-202-202-202-202-</td><td>2.4</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Mobility         log Pod for individual ingredients         log Pod for individual ingredients         Poten Para3/mol 20°C           1, 2-benzisothiazol-3(2H)-one         0,97         Unlikely, I           Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)         Unlikely, I         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           Does not contain substances that fulfil the PBT/VPVB criteria.         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         Indix 201-202-202-202-202-202-202-202-202-202-	2.4								
for individual ingredients         Parm3/mol 20°C           1,2-benzisothiazol-3(2H)-one         0,97         Unlikel           Reaction mass of 5-chtoro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)         Unlikel         Unlikel           1,2-benzisothiazol-3(2H)-one         1,05         Unlikel           1,2-benzisothiazol-3(2H)-one         1,05         Unlikel           12.5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)         Does not contain substances that fulfil the PBT/VPVB criteria.           12.6         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         .           2.7         OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.         .         .           2.7         OTHER ADVERSE EFFECTS: - Photochemical ozone creation potential: Not available.         .         .           3.1         WASTE TREATMENT METHODS:Directive 2008/98/EC=Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and protection measures, see section 8.           LER code         Description         Type of waste	for individual ingredients         Parm3/mol 20°C           1,2-benzisothiazol-3(2H)-one         0,97           Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6]         Unlikely, I           1,2-benzisothiazol-3(2H)-one         1,05         Unlikely, I           12.5         RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PBT/vPvB criteria.         Unlikely, I           12.6         ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.            12.7         OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.             - Earth global warming potential: Not available.              13.1         WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.           LER code         Description         Type of waste           Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging ab									
1,2-benzisothiazol-3(2H)-one       0,97       Unlikel         Reaction mass of 5-chloro-2-methyl-2H-isothiazolin-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-(2H)-one       0,45       Unlikel         1,2-benzisothiazol-3-(2H)-one       1,05       Unlikel         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PBT/vPvB criteria.       Unlikel         12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       Unlikel         12.7       OTHER ADVERSE EFFECTS: -Ozone depletion potential: Not available.       -Photochemical ozone creation potential: Not available.       Not available.         2.5       EETH global warming potential: Not available.       Not available.       -Earth global warming potential: Not available.         13.1       WASTE TREATMENT METHODS.Directive 2008/98/EC-Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local an national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers: Directive 94/62/EC-2015/720/EU. Decision 2000/532/EC-2014/955	12-benzisothiazol-3(2H)-one       0,97       Unlikely, I         Reaction mass of 5-chloro-2-methyl-2H-isothiazoln-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 220-239-6]       Unlikely, I         (3:1)       1,2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:)       Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES:       This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS:      ocone depletion potential:         Not available.      Photochemical ozone creation potential:         Not available.      Photochemical ozone creation potential:         Not available.      Disposal CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC-Regulation (EU) no. 1357/2014:         Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste <tr< td=""><td></td><td></td><td>ients</td><td></td><td>log Poc</td><td></td><td></td></tr<>			ients		log Poc				
Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)       Unlikel         12-5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PT/VPVB criteria.       Unlikel         12-6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       Unlikel         12-7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available. - Earth global warming potential: Not available. - Earth global warming potential: Not available.       - Photochemical ozone creation potential: Not available.         13-1       WASTE TREATMENT METHODS:Directive 2008/98/EC-Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste Non-hazardous         Disposal of empty containers:Directive 94/62/EC-2015/720/EU. Decision 2000/532/EC-2014/955/EU: # Emptied containers and packaging abould be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC-2014/955/EU: # Emptied cont	Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)       Unlikely, I         Iter 1, 2-benzisothiazol-3(2H)-one       1,05       Unlikely, I         Iter 2, 200, 200, 200, 200, 200, 200, 200,					0.97		Unlikelv. lo		
1,2-benzisothiazol-3(2H)-one       1,05       Unlikel         12.5       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006:) Does not contain substances that fulfil the PBT/VPVB criteria.       12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.       12.7         0THER ADVERSE EFFECTS: Ozone depletion potential: Not available. Earth global warming potential: Not available.      Photochemical ozone creation potential: Not available.      Earth global warming potential: Not available.         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC-Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification - packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging adopt the same measures as for the product in itself. Procedures for neut	1,2-benzisothiazol-3(2H)-one       1,05       Unlikely, 1         12.5       RESULTS OF PBT AND VPVB ASSESMENT:(Annex XIII of Regulation (EC) no. 1907/2006.) Does not contain substances that fulfil the PBT/VPvB criteria.       12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available. - Earth global warming potential: Not available. - Earth global warming potential: Not available.       -         13.1       WASTE TREATMENT METHODSS       13.1         WASTE TREATMENT METHODSS       Indication of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste Non-hazardous         Disposal of empty containers:Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. For exposure controls and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 0 1 of Decision 2000/532/EC-2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The		Reaction mass of 5- isothiazolin-3-one [E methyl-2H-isothiazo	-chloro-2-methyl- EC 247-500-7] ar	nd 2-			Unlikely, lo		
12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006;) Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS: -Ozone depletion potential: Not available. -Enth global warming potential: Not available. -Earth global warming potential: Not available. -Earth global warming potential: Not available.         2.1       TAKE TREATMENT METHODS: Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste Non-hazardous         Disposal of empty containers.Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	12.5       RESULTS OF PBT AND VPVB ASSESMENT: (Annex XIII of Regulation (EC) no. 1907/2006;) Does not contain substances that fulfil the PBT/VPVB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES; This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS; - Ozone depletion potential; Not available.         - Photochemical ozone creation potential; Not available.       - Earth global warming potential; Not available.         - ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS: Directive 2008/98/EC-Regulation (EU) no. 1357/2014; Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste Non-hazardous         Disposal of empty containers.Directive 94/62/EC-2015/720/EU, Decision 2000/532/EC-2014/955/EU; # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying			3(2H)-one		1.05		Unlikely, la		
Does not contain substances that fulfil the PBT/vPvB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available. - Photochemical ozone creation potential: Not available. - Earth global warming potential: Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emplied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With containinated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	Does not contain substances that fulfil the PBT/vPvB criteria.         12.6       ENDOCRINE DISRUPTING PROPERTIES: This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS: Ozone depletion potential: Not available. Photochemical ozone creation potential: Not available. Earth global warming potential: Not available.         CCTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS.Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging . Adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product;	2.5			SESMENT: (Ar		) no. 1907/2006:)	<b>,</b>		
This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available. - Photochemical ozone creation potential: Not available. - Earth global warming potential: Not available. - Earth global warming potential: Not available. ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8. LER code Description Type of waste Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification in packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	This product does not contain substances with endocrine disrupting properties identified or under evaluation.         12.7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available.         - Photochemical ozone creation potential: Not available.       - Photochemical ozone creation potential: Not available.         - Earth global warming potential: Not available.       - Earth global warming potential: Not available.         Section 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:		Does not contain sub	stances that fulfil t	he PBT/vPvB	criteria.				
12.7       OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available. - Photochemical ozone creation potential: Not available. - Earth global warming potential: Not available.         2.5       - Earth global warming potential: Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	12.7       OTHER ADVERSE EFFECTS: -Ozone depletion potential: Not available. -Photochemical ozone creation potential: Not available. -Earth global warming potential: Not available. -Earth global warming potential: Not available. ECTION 13: DISPOSAL CONSIDERATIONS          13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8. LER code	2.6								
Ozone depletion potential: Not available.     Photochemical ozone creation potential: Not available.     Earth global warming potential: Not available.     ECTION 13: DISPOSAL CONSIDERATIONS      WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.     LER code     Description     Type of waste     Non-hazardous     Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.     Procedures for neutralising or destroying the product:	- Ozone depletion potential: Not available.     - Photochemical ozone creation potential: Not available.     - Earth global warming potential: Non-hazardous point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.     - ER code	0.7			es with endocr	ine disrupting properties ident	tified or under evaluation.			
Not available.       - Photochemical ozone creation potential: Not available.         - Earth global warming potential: Not available.       - Earth global warming potential: Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description       Type of waste         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification is packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:	Not available.       - Photochemical ozone creation potential: Not available.         - Earth global warming potential: Not available.       - Earth global warming potential: Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13:1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	2.7								
Not available.         - Earth global warming potential: Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recyc Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispos accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste         Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	Not available.         - Earth global warming potential: Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:			ioterniar.						
- Earth global warming potential: Not available.   ECTION 13: DISPOSAL CONSIDERATIONS  13.1  WASTE TREATMENT METHODS: Directive 2008/98/EC~Regulation (EU) no. 1357/2014:  Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycle Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.  LER code Description Type of waste Non-hazardous Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification or packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	-Earth global warming potential: Not available.   CTION 13: DISPOSAL CONSIDERATIONS  I3.1  VASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.  LER code Description Type of waste Non-hazardous Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:		- Photochemical oz	one creation pote	ential:					
Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycle Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:	Not available.         ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:									
ECTION 13: DISPOSAL CONSIDERATIONS         13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycle Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	Image: Construct of the			<u>ing potential:</u>						
13.1       WASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014: Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste         Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:	MASTE TREATMENT METHODS:Directive 2008/98/EC~Regulation (EU) no. 1357/2014:         Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:									
Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycl         Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and dispose accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers: Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:	Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed accordance with current local and national regulations. For exposure controls and personal protection measures, see section 8.         LER code       Description         Type of waste       Non-hazardous         Disposal of empty containers: Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:       # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:				Directive 0000	100/EC Desulation (EU) as	4257/2044			
Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations.The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:	Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU:         # Emptied containers and packaging should be disposed in accordance with currently local and national regulations.The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination.With contaminated containers and packaging, adopt the same measures as for the product in itself.         Procedures for neutralising or destroying the product:	13.1	Take all necessary measures to prevent the production of waste whenever possible. Analyse possible methods for revaluation or recycling Do not discharge into drains or the environment, dispose at an authorised waste collection point. Waste should be handled and disposed i							
Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	Disposal of empty containers:Directive 94/62/EC~2015/720/EU, Decision 2000/532/EC~2014/955/EU: # Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:		LER code	Desci	ription			Type of waste		
# Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	# Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:							Non-hazardous		
# Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:	# Emptied containers and packaging should be disposed in accordance with currently local and national regulations. The classification of packaging as hazardous waste will depend on the degree of empting of the same, being the holder of the residue responsible for their classification, in accordance with Chapter 15 01 of Decision 2000/532/EC, and forwarding to the appropriate final destination. With contaminated containers and packaging, adopt the same measures as for the product in itself. Procedures for neutralising or destroying the product:		Disposal of empty of	ontainers:Directi	ve 94/62/EC~	-2015/720/EU. Decision 20	00/532/EC~2014/955/E	U:		
			# Emptied containers packaging as hazard classification, in acco contaminated contain <u>Procedures for neur</u>	and packaging sh ous waste will dep rdance with Chapt ers and packaging tralising or destro	nould be disposed end on the deg ter 15 01 of De g, adopt the sa bying the proc	sed in accordance with curren gree of empting of the same, b cision 2000/532/EC, and forw me measures as for the produ luct:	tly local and national regu being the holder of the res arding to the appropriate f	lations.The classification of idue responsible for their		

accorda	ance with Regulation (ÈC)	No. 1907/2006 and Regulation (EU) No. 202	0/878	(Language:E
	isaval	DUEPOL ACQUA SUELOS SATINADO		
$\square$	pinturas	Code : 1656		
ersion	n: 3 Rev	l rision: 11/03/2024	Previous revision: 23/12/2022	Date of printing: 11/03/20
ECTION	14: TRANSPORT INFO	ORMATION		
14.1	UN NUMBER OR ID			
	Not applicable			
14.2	UN PROPER SHIPP	ING NAME:		
	Not applicable			
14.3	TRANSPORT HAZA	RD CLASS(ES):		
	Transport by road (A	DR 2023) and		
	Transport by rail (RII	<u>) 2023):</u>		
	No reglamented			
	Transport by sea (IM	<u>DG 40-20):</u>		
	No reglamented	Q (ATA 0004)		
	Transport by air (ICA	<u>O/IATA 2021):</u>		
	No reglamented Transport by inland w			
	No reglamented	<u>raterways (ADN).</u>		
14.4	PACKING GROUP:			
<b>T.T</b>	No reglamented			
4.5	ENVIRONMENTAL F	AZARDS:		
	Not applicable (not clas	ssified as hazardous for the environment).		
14.6	SPECIAL PRECAUT	IONS FOR USER:		
	upright and secure.		case of accident or spill. Always transport in c	losed containers that are
4.7	MARITIME TRANSP Not applicable.	ORT IN BULK ACCORDING TO IMO IN	<u>NSTRUMENTS:</u>	
CTION	15: REGULATORY INF	ORMATION		
5.1	SAFETY, HEALTH A	ND ENVIRONMENTAL REGULATION	S/LEGISLATION SPECIFIC FOR THE S	UBSTANCE OR MIXTUR
	The regulations applica	able to this product generally are listed thro	ughout this Safety Data Sheet.	
		facture, placing on market and use:		
	See section 1.2			
	Tactile warning of da			
		ssification criteria are not met).		
	Child safety protectio	<u>m:</u> ssification criteria are not met).		
	VOC information on t			
			nit value 2004/42/EC-IIA cat. j) Two-pack perl	ormance coating water-
	borne. is VOC max. 14		······································	<b>3</b> ,
	OTHER REGULATIC	<u>DNS:</u>		
	Not available.			
		herent in major accidents (Seveso III):		
	See section 7.2			
	Other local legislation			
5.0	CHEMICAL SAFETY	rify the possible existence of local regulation	ons applicable to the chemical.	
5.2		essment has not been carried out for this mi	ivture	
	A chemical salety asse			

$\prec$	<b>isava</b>	Code : 1656			
rsion	n: 3 Rev	ision: 11/03/2024	Previous revision: 2	3/12/2022	Date of printing: 11/03/202
TION	16 : OTHER INFORMA	TION			
.1		SES AND NOTES REFERENCE			
	H301 Toxic if swallowed H315 Causes skin irritat toxic to aquatic life. H4: <u>Notes related to the id</u> Note B : Some substan these solutions require have a general designat solution on the label. U <u>EVALUATION OF TH</u> See sections 9.1, 11.1		Fatal in contact with skin. H314 Causes in reaction. H318 Causes serious eye lasting effects. EUH071 Corrosive to <u>elling of the substances or mixture</u> in the market in aqueous solutions at ince the hazards vary at different cor %'. In this case the supplier must that the percentage concentration is <u>GER OF MIXTURES:</u>	es severe skin e damage. H33 the respiratory es: various concer ncentrations. In state the perce	0 Fatal if inhaled. H400 Ver y tract. htrations and, therefore, h Part 3 entries with Note B entage concentration of the
	It is recommended for a	RAINING APPROPRIATE FOR W III staff that will handle this product to and interpretation of Safety Data She	carry out a basic training in occupati		prevention, in order to
		REFERENCES AND SOURCES F			
		Agency: ECHA, http://echa.europa.e∟ Inion Law, http://eur-lex.europa.eu/ s, (AGCIH, 2021).	1/		
	· European agreement	on the international carriage of dange Dangerous Goods Code IMDG inclu			
		d acronyms that can be used (but no	t necessarily used) in this Safety Dat	a Sheet:	
	<ul> <li>EINECS: European In</li> <li>ELINCS: European Li</li> <li>CAS: Chemical Abstra</li> <li>UVCB: Substances of</li> <li>SVHC: Substances of</li> <li>PBT: Persistent, bioac</li> <li>vPvB: Very persistent</li> <li>VOC: Volatile Organic</li> <li>DNEL: Derived No-Eff</li> <li>PNEC: Predicted No-I</li> <li>LC50: Lethal concentr</li> <li>LD50: Lethal dose, 50</li> <li>UN: United Nations O</li> <li>ADR: European agree</li> <li>RID: Regulations como</li> <li>IMDG: International Mi</li> <li>IATA: International Air</li> </ul>	cumulable and toxic substances. and very bioaccumulable substances Compounds. ect Level (REACH). Effect Concentration (REACH). ation, 50 percent. percent. "ganisation. ment concerning the international ca serning the international transport of o aritime code for Dangerous Goods. Transport Association.	nical Substances. n Chemical Society). omplex reaction products or biologica s. rriage of dangeous goods by road.		
	SAFETY DATA SHE				
	Safety Data Sheet in ad HISTORIC: Version: 1	cordance with Article 31 of Regulatic <u>REVISION:</u> 24/12/2021	on (EC) No. 1907/2006 (REACH) and	Annex of Reg	julation (EU) No. 2020/878.
	Version: 2 Version: 3	23/12/2022 11/03/2024			
		us Safety Data Sheet: numerical, methodological and norm	ative changes since the previous ver	sion of the pre	sent Safety Data Sheet are
ditions dling i slation	mation of this Safety Data sare beyond our knowled instruction. It is always th	a Sheet, is based on the present state ge and control. The product is not to e responsibility of the user to take all Safety Data Sheet is meant as a desc operties	be used for other purposes than those necessary steps in order to fulfil the	se specified, w demand laid d	ithout first obtaining written lown in the local rules and